Stuart Nelson
Stuart Nelson is a Technical Lead of Analytical Control Strategy at Eli Lilly. Stuart has over a decade of industry experience in drug development for several biologic modalities. He joined Prevail Therapeutics in 2018 (acquired by Lilly in 2021), holding increasing levels of responsibility over the last 5 years. His most recent contributions were as part of the Gene Therapy CMC and analytical development teams, helping advance multiple programs from pre-IND to clinical dosing. Prior to Prevail, Stuart held positions at Kanyos Bio (Merged with Anokion) and MassBiologics.

No Digital PCR Festival would be complete without exploring the use of digital PCR in biopharmaceutical manufacturing. Discover how scientists apply dPCR in cell and gene therapies where precision and sensitivity are of highest importance.

  • Opening remarks from QIAGEN
  • PCR in Biopharma - Past, Present, and the Future
    Speaker: Prof Dr. Mikael Kubista, Institute of Biotechnology, Czech Academy of Sciences, Czech Republic
  • Digital PCR Empowers Liquid Biopsy for Comprehensive Solid Tumor Management: Integrating Circulating Tumor Cells and Extracellular Vesicles
    Speaker: Prof Dr. Hsian-Rong Tseng, David Geffen School of Medicine at UCLA, USA
  • Multiplex dPCR offers quantitative viral vector genome integrity evaluation
    Speaker: Assist. Prof. Dr. David Dobnik, Niba Labs d.o.o. , Slovenia
  • Digital PCR Applications for Gene Therapy Products Including AAV Quantitation
    Speaker: Mr. Stuart Nelson, Eli Lilly and Company, USA
  • Quantifying AAV vector genome titer in process  ̶  intermediate samples by digital PCR and digital droplet PCR (d/dPCR)
    Speaker: Mr. Chieme Kennedy Okechukwu, National Resilience, USA
  • Closing remarks from QIAGEN
Dr. Mikael Kubista and 4 other experts